1. Market Research
  2. > Pharmaceutical
  3. > Drug Discovery and Development Market Trends
  4. > Malignant Mesothelioma Global Clinical Trials Review, H1, 2016

Malignant Mesothelioma Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, “Malignant Mesothelioma Global Clinical Trials Review, H1, 2016" provides an overview of Malignant Mesothelioma clinical trials scenario. This report provides top line data relating to the clinical trials on Malignant Mesothelioma. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table Of Contents

Malignant Mesothelioma Global Clinical Trials Review, H1, 2016
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Report Guidance 5
Clinical Trials by Region 6
Clinical Trials and Average Enrollment by Country 7
Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9
Top Five Countries Contributing to Clinical Trials in Europe 10
Top Countries Contributing to Clinical Trials in North America 11
Top Countries Contributing to Clinical Trials in Middle East and Africa 12
Top Countries Contributing to Clinical Trials in Central and South America 13
Clinical Trials by G7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 14
Clinical Trials by Phase in G7 Countries 15
Clinical Trials in G7 Countries by Trial Status 16
Clinical Trials by E7 Countries: Proportion of Malignant Mesothelioma to Oncology Clinical Trials 17
Clinical Trials by Phase in E7 Countries 18
Clinical Trials in E7 Countries by Trial Status 19
Clinical Trials by Phase 20
In Progress Trials by Phase 21
Clinical Trials by Trial Status 22
Clinical Trials by End Point Status 23
Subjects Recruited Over a Period of Time 24
Clinical Trials by Sponsor Type 25
Prominent Sponsors 26
Top Companies Participating in Malignant Mesothelioma Therapeutics Clinical Trials 27
Prominent Drugs 28
Latest Clinical Trials News on Malignant Mesothelioma 29
Jun 04, 2016: Five Prime Therapeutics Announces Updated Data in Mesothelioma Patients from Ongoing Phase 1b Trial of FP-1039 Presented at 2016 ASCO Annual Meeting 29
Apr 20, 2016: Bionomics Presents Cancer Drug Data at Annual American Association for Cancer Research Conference 29
Clinical Trial Profile Snapshots 31
Appendix 297
Abbreviations 297
Definitions 297
Research Methodology 298
Secondary Research 298
About GlobalData 299
Contact Us 299
Disclaimer 299
Source 300

List of Tables
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region, 2016* 6
Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9
Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10
Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries, 2016* 11
Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2016* 12
Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries, 2016* 13
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase, 2016* 20
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28

List of Figures
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Region (%), 2016* 6
Malignant Mesothelioma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8
Malignant Mesothelioma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9
Malignant Mesothelioma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10
Malignant Mesothelioma Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11
Malignant Mesothelioma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2016* 12
Malignant Mesothelioma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2016* 13
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, G7 Countries (%), 2016* 14
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15
Malignant Mesothelioma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16
Proportion of Malignant Mesothelioma to Oncology Clinical Trials, E7 Countries (%), 2016* 17
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18
Malignant Mesothelioma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20
Malignant Mesothelioma Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21
Malignant Mesothelioma Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22
Malignant Mesothelioma Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24
Malignant Mesothelioma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27
Malignant Mesothelioma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28
GlobalData Methodology 298

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

Clinical Trial Imaging Market by Product & Services, Modality, End User - Global Forecast to 2021

  • $ 5650
  • Industry report
  • December 2016
  • by MarketsandMarkets

The global clinical trial imaging market is projected to reach USD 1069.7 million by 2021 from USD 773.4 million in 2016, at a CAGR of 6.7% from 2016 to 2021. Increase in R&D spending and growth in the ...

Global Clinical Trials Market

Global Clinical Trials Market

  • $ 4250
  • Industry report
  • December 2016
  • by Mordor Intelligence LLP

The global clinical trials market has been estimated to reach USD 14.2 billion in 2016 and is projected to reach around USD 22 billion by the year 2021, growing at a CAGR (compounded annual growth rate) ...

Oncology Devices - Medical Devices Pipeline Assessment, 2016

Oncology Devices - Medical Devices Pipeline Assessment, 2016

  • $ 4000
  • Industry report
  • December 2016
  • by GlobalData

Oncology Devices - Medical Devices Pipeline Assessment, 2016 Summary GlobalData's Medical Devices sector report, “Oncology Devices - Medical Devices Pipeline Assessment, 2016" provides an overview of ...


ref:plp2016

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.